Discovery of Novel Proteasome Inhibitors Using a High-Content Cell-Based Screening System

Irena Lavelin1, Avital Beer2, Zvi Kam1, Varda Rotter1, Moshe Oren1, Ami Navon2, Benjamin Geiger1*

1 Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel, 2 Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel

Abstract

The regulated degradation of damaged or misfolded proteins, as well as down-regulation of key signaling proteins, within eukaryotic and bacterial cells is catalyzed primarily by large, ATP-dependent multimeric proteolytic complexes, termed proteasomes. Inhibition of proteasomal activity affects a wide variety of physiological and pathological processes, and was found to be particularly effective for cancer therapy. We report here on the development of a novel high throughput assay for proteasome inhibition using a unique, highly sensitive live-cell screening, based on the cytoplasm-to-nucleus translocation of a fluorescent proteasome inhibition reporter (PIR) protein, consisting of nuclear localization signal-deficient p53 derivative. We further show here that mdm2, a key negative regulator of p53 plays a key role in the accumulation of PIR in the nucleus upon proteasome inhibition. Using this assay, we have screened the NCI Diversity Set library, containing 1,992 low molecular weight synthetic compounds, and identified four proteasome inhibitors. The special features of the current screen, compared to those of other approaches are discussed.

Introduction

The proteasome is the major proteolytic complex, responsible, in eukaryotic cells, for the degradation of a multitude of cellular proteins. This multi-protein complex, present in both the cytoplasm and the nucleus, catalyzes the ATP-dependent proteolysis of short-lived regulatory proteins, as well as the rapid elimination of damaged and abnormal proteins [1,2]. The 26S proteasome is a large complex of ~2.5 MDa. Based on biochemical analyses, this complex can be dissociated into two functionally distinct subcomplexes, the 20S core particle (CP) which is the proteolytic component, and the 19S regulatory particle (RP), that is responsible for recognizing, unfolding, and translocating polyubiquitinated substrates into the 20S CP, where they are degraded.

The 20S CP is a 670 kDa barrel-shaped protein complex made up of four stacked, seven-membered rings (4x7 subunits), two outer α rings and two inner β rings (α1,2β3,β2,3,α1,2). The two matching α rings are situated in the outer rims of the barrel, facing the 19S regulatory complex. The proteolytic active sites are located on the two identical β-rings, which are positioned in the center of the 20S complex [3,4]. In eukaryotes, the catalytic activities of the proteasomes are confined to only three of the β-subunits. Although proteasomes can hydrolyze the amide bonds between most amino acids, proteolytic activities measured using fluorogenic substrates define three distinct (although not conclusive) cleavage preferences [5]: β2 possesses trypsin activity (i.e., cleaving after hydrophobic residues); and β1 has “caspase-like” or “post-acidic” activity. In all three active β-subunits, proteolytic activity is associated with their N-terminal threonine residue, which acts as a nucleophile in peptide-bond hydrolysis.

The use of proteasome inhibitors as drug candidates emerged from the observation that at specific concentrations, they can induce apoptosis in certain leukemia- and lymphoma-derived cells [6,7] without similarly affecting their non-transformed counterparts. Further development and clinical trials led to the approval of the modified boronic dipeptide Pyz-Phe-boroLeu, known as Bortezomib or Velcade®, as a drug for the treatment of multiple myeloma [8,9,10,11]. Most synthetic proteasome inhibitors are short peptides that mimic protein substrates. Typically, the pharmacophore that reacts with and inhibits the threonine residue in the 20S proteasome’s active site is bound to the carboxyl residue of the peptide [12]. Some of the typical synthetic inhibitors are peptide aldehydes, peptide vinyl sulfones, peptide boronates, and peptide epoxyketones [for review, see [13]]. Most notable among the natural, bacterially derived non-peptide inhibitors is clasto-lactacystin-β-lactone (Omuralide) [14]. Related drugs such as Salinosporamide A (NPI-0052) and Carfilzomib (PR-171) are currently in advanced clinical trials [15,16,17]. However, despite the extensive efforts invested in proteasome inhibitor development, there is a growing need for novel inhibitory molecules, due to the emergence of drug-resistant cells and the variable effects of existing inhibitors on different cells.

Most of the current assays for proteasome inhibition are based on cell-free assays [18,19], which require purification of 26S or
20S proteasomes from different sources. Such assays may, in principle, be adapted to high-throughput screens, yet they may fail to predict the inhibitory activity in live cells. To overcome this problem, cell-based screens have been incorporated into the drug discovery process. For example, a modified “classical” method for measurement of the chymotrypsin-like, trypsin-like, or caspase-like proteasome activities in cultured cells [20] is currently available from Promega Corporation. A number of fluorescent reporter molecules have been also usefully employed to monitor the activity of the proteasome. Dantuma et al constructed a fusion of GFP to Ubiquitin (Ubi[G76V]-GFP) using a standard peptide bond at the N-terminus [21]. Another proteasome sensor construct, which is a GFP fusion to an artificial peptide, CLI, identified in yeast has been designed by Bence et al [22]. The Andreata group and BD Biosciences Clontech has introduced a sensor cell line expressing a GFP fusion protein with a fragment of the mouse ornithine decarboxylase (MODC), which is degraded by the proteasome without the requirement for ubiquitination [23]. An additional reporter cell line, based on the stable expression of a p27kkip1-GFP fusion was recently employed for the discovery of a novel proteasome inhibitor, argymin A [24]. The common feature of most of these GFP-fused reporters is that they are based on proteins rapidly degraded by the proteasome under normal conditions, leading to very low fluorescence of the cells, while following inhibition of proteasome activity, the overall fluorescent signal of the cells rapidly increases as a result of accumulation of the reporter proteins.

In this article, we describe a novel, image-based screening approach, which utilizes an H1299 reporter cell line, stably expressing a fluorescent “Proteasome Inhibition Reporter” (PIR) protein. The screen is based on the finding that upon inhibition of proteasomal activity, this fluorescent reporter molecule translates from the cytoplasm to the nucleus. Our findings demonstrate that this approach is highly sensitive, and compatible with high throughput microscopy. In the screen reported herein, we tested the Diversity Set of the NIH/NCI chemical library, and identified four compounds with pronounced proteasome inhibitory activity, three of which are novel inhibitors.

Materials and Methods

DNA Constructs, Generation of a Stable Reporter Cell Line and Transient Transfection

To construct a YFP-tagged Proteasome Inhibitor Reporter (PIR) protein, cDNA encoding a full-length human p53 R175H mutant was amplified by PCR from a cDNA clone, and three consecutive lysine residues in the bipartite Nuclear Localization Signal (NLS) were replaced with alanines by PCR-based, site-directed mutagenesis [25] [26]. The DNA fragment was cloned into the BglII and NotI sites of pLPCX retroviral vector (Clontech) in-frame to the N-terminus of the yellow fluorescent protein (YFP), using the NotI/Clal restriction sites. The PIR protein was expressed in an H1299 non-small cell lung carcinoma cell line, following retroviral infection, and the cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum, 2 mM glutamine and 1% penicillin-streptomycin (all from Sigma-Aldrich) in a humidified atmosphere of 5% CO2 at 37°C. Fluorescent cells were isolated by flow cytometry, and single-cell cloning was used to generate a morphologically uniform cell population.

Plasmids for the expression of human MDM2 were kindly provided by B. Vogelstein (wild type MDM2), A. Levine [MDM2 Δ9-58] and A. Ciechanover [MDM2 Ser 440]. Transfections employing plasmid DNA were carried out using Lipofectamine 2000™ reagent (Invitrogen) as per the manufacturer’s instructions. For RNA interference, PIR cells were transfected with 50 pM control or MDM2 siRNA oligonucleotides (Dharmacon, ON-TARGETplus SMARTpool), with Dharmafect 2 (Dharmacon) according to the manufacturer’s protocol.

Immunofluorescence Microscopy

Cells were cultured on glass coverslips, fixed, and permeabilized for 2 min in phosphate-buffered saline (PBS) containing 0.5% Triton X-100 and 3% formaldehyde, and post-fixed with 3% formaldehyde in PBS for 30 min. The cells were then rinsed and stained with polyclonal anti-β-catenin antibody (Sigma) or a mixture of anti-MDM2 monoclonal antibodies SMP14, 2A10, and 4B11 for 1 h (hybridoma cells were kindly provided by A. Levine), washed, and further incubated with Cy3-conjugated goat antimouse IgG (Enco). Images were acquired using the DeltaVision system (Applied Precision Inc.).

Compound Library

The chemical compound library screened here for proteasomal inhibitors consisted of the NCI Diversity Set, containing 1,992 low molecular weight synthetic compounds selected from and representing nearly 140,000 compounds available from the NCI DTP chemical library (http://dtp.nci.nih.gov/branches/dscb/diversity_explanation.html).

The library compounds were dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM, placed in 96-well plates, and stored at −70°C for future use.

Image-Based Screening Assay for Proteasome Activity

PIR-expressing H1299 cells were seeded at a density of 800 cells per well in 384-well assay plates (F-bottom, µClear, black, tissue-culture-treated) (Greiner Bio-One). Cells were cultured for 24 h and treated with the library compounds at two concentrations (1 and 10 µM) in RPMI 1640. In each assay plate, cells in 24 wells treated with 0.2% DMSO alone were used as controls. As a positive control, 1 µM MG132 was added to a single column of the assay plate. Following 12 hours of incubation, cells were fixed in 3% paraformaldehyde for 20 min, then washed with PBS and screened for localization of the fluorescent PIR protein.

Microscope Automation and Image Processing

WiScanD™ Cell Imaging System (Idea Bio-Medical) was used for this screen [27]. The system is based on an IX71 microscope (Olympus), equipped with a fast laser AutoFocus device [28] and an automated stage. Thirty-six fields were acquired from every well using a 60x/0.9 air objective, stored, and tiled into montages to detect consistent effects. Scoring of the nuclear translocation of the fluorescent PIR protein was carried out manually.

In Vitro Proteasome Activity Assay

For measuring proteasome activity, purified 20S or 26S proteasomes prepared from rabbit muscles were incubated at a final concentration of 16 nM, with 100 µM fluorogenic 7-amiido-4-methylcoumarin (AMC) tetrapeptide substrate Suc-LLVY-AMC (Bachem) and the stated concentration of the hit compounds in the presence of 100 µl of assay buffer (50 mM Hepes, 5 mM MgCl2, 2 mM ATP and 1 mM DTT). The well-documented proteasomal inhibitor MG132 was used as a positive control, and an equivalent volume of solvent as a negative control. The time-dependent increase of hydrolyzed AMC groups was measured in a 96-well plate equilibrated to 37°C, using a Varioscan multi-well plate reader (Thermo Fisher Scientific, Inc.) in a kinetic mode, in which
the recording intervals were set to 1 minute. The excitation wavelength was 370 nm; fluorescence emission was recorded at 465 nm.

Immunoblotting
H1299-PIR cells were lysed with radioimmune precipitation assay buffer (1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris, pH 8.0) containing a protease inhibitor cocktail from Roche Applied Science. Protein extracts were subjected to 8% SDS-PAGE, transferred to a nitrocellulose membrane (Whatman), and probed with monoclonal anti-p53 (DO1, Santa Cruz Biotechnology), anti-ubiquitin (Covance), anti-β-catenin (Sigma) and anti-β-tubulin (Sigma) primary antibodies.

For sub-cellular fractionation, cells were harvested and resuspended in ice-cold hypotonic lysis buffer [10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, supplemented with a complete protease inhibitor cocktail (Roche)], incubated on ice for 15 min, then NP40 was added, to a final concentration of 0.6%. The samples were vortexed for 10 s and immediately centrifuged at 12,000 g for 30 s. The supernatant (cytoplasmic fraction) was transferred to a fresh tube. The nuclei pellet was washed once with hypotonic lysis buffer, and lysed with SDS sample buffer (100 mM Tris–HCl pH 6.8, 2% SDS, 100 mM DTT, and 10% glycerol).

Cell Viability Assay
The effect of each hit compound on cell viability was tested at 11 different concentrations, ranging from 0.1–100 μM. PIR cells were plated onto 384-well microplates for 24 hours, and then treated for 48 h with the library compounds. Cell viability was determined using the colorimetric AlamarBlue® (Invitrogen) viability assay, according to the manufacturer’s instructions. Results are expressed as GI50; namely, the compound concentration that reduces the AlamarBlue® score by 50%, compared to untreated controls.

Results
Development of an H1299-PIR Reporter Cell Line and Its Application for an Image-Based, High-Throughput Screening for Proteasome Inhibitors
The PIR protein, used here for proteasome inhibitor screening, was constructed of yellow fluorescent protein (YFP) fused to the C-terminus of the human p53 R175H mutant. The cytoplasm-to-nucleus transport of this p53 mutant was attenuated by additional triple mutation in the bipartite NLS in which three consecutive lysine residues were replaced with alanines (K319A, K320A, and K321A), as described by O’Keefe et al [29]. In agreement with previous reports, under normal cell culture conditions, this point mutation leads to cytoplasmic localization of the PIR protein in H1299 cells [29,30], confirming that the three basic residues at position 319–321 are indeed part of a nuclear localization signal. However, upon treatment with known proteasome inhibitors (e.g. MG132, Bortezomib and ALLN), PIR translocates into the nucleus in a manner reminiscent of p53 mutated in its NLS (Fig. 1B upper panel) [31]. β-catenin, whose cellular levels are primarily regulated by the proteasome, underwent similar nuclear translocation in response to proteasome inhibition (Fig. 1B, lower panel), yet this was accompanied by significant stabilization and increase in its quantity [32] unlike PIR, whose overall levels did not markedly change. To validate these results, we quantified the levels of PIR in the nuclear and cytoplasmic fractions of treated and control H1299-PIR cells using immunoblotting. This assay confirmed our microscopy-based observation, and pointed to a ~3-fold increase in the nuclear/cytoplasmic ratio of PIR, in response to MG132 treatment (Fig. 1C).

To assess the sensitivity of the PIR cell-based assay, H1299-PIR cells were incubated for 8 hours with different concentrations (0.01–10 μM) of known proteasome inhibitors (MG132 and Bortezomib). The cells were then fixed and scored for nuclear translocation of PIR. The score (EC50) refers to the concentration of inhibitor needed to induce nuclear translocation of PIR in 50% of the treated cells. This test indicated that in our assay, the EC50 values for MG132 and Bortezomib were 0.5 μM, and 0.05 μM, respectively. These values favorably compare with those reported for other detection systems, such as the commercial Living Colors HEK 293 ZsGreen Proteasome Sensor system (Clontech), which detects MG132 at 2.5 μM (after 20 hours of treatment using flow cytometry) [23], or for the UbilG76V-GFP-based reporter system (BioImage), in which the reported EC50 value for MG-132 was approximately 1.0 μM [21]. Thus, H1299-PIR cells appear to be sensitive reporters, capable of detecting the activity of proteasome inhibitors in a cell-based assay.

Nuclear Accumulation of Endogenous MDM2 in Response to Proteasome Inhibition Is Responsible for PIR Nuclear Translocation
To further characterize the mode of PIR nuclear translocation upon proteasome inhibition, we have considered the possibility that proteasome-sensitive p53 binding proteins, are responsible for carrying PIR into the nucleus. Towards this end, MDM2, a p53 E3 ubiquitin ligase and a known target of proteasome-dependent degradation, was transfected into PIR cells, and its localization was assessed by immunofluorescence microscopy. As expected, endogenous MDM2 labeling in the PIR-H1299 cells was relatively faint and mostly nuclear while PIR was mainly localized to the cytoplasm (Figure 2a). In contrast, in the cells transfected with wild type MDM2, both the fluorescent PIR and MDM2 translocated to the nucleus. This suggests that MDM2 can transport NLS-deficient PIR from the cytoplasm into the nucleus, perhaps via the NLS of MDM2, consistently with previous studies suggesting that MDM2 can promote the nuclear import of ANLS p53 [31]. Interestingly, PIR remained cytoplasmic in cells over-expressing a mutated MDM2 lacking the p53 binding site (MDM2 Δ9-58), suggesting that the interaction between the two proteins is needed for their cotranslocation to the nucleus. On other hand, MDM2 mutant with point mutation that abolishes its E3 ubiquitin ligase function (MDM2 Ser440) induced PIR nuclear localization similar to the wild type molecule.

To check whether MDM2 expression is critical for PIR nuclear translocation, we performed siRNA-mediated knockdown of MDM2 expression in PIR-cells, and then treated the cells with proteasome inhibitors (Figure 2b). It was found that when MDM2 levels in the knocked-down cells were reduced, PIR remained cytoplasmic even following treatment with proteasome inhibitors, indicating that MDM2 is an essential player in the nuclear localization of NLS-deficient PIR.

Screening for Novel Proteasome Inhibitors in the Diversity Set of the NIH/NCI Chemical Library
To assess the potential use of the cytoplasm-to-nucleus translocation of PIR in high-throughput, microscopy-based screening for novel proteasome inhibitors, we tested 1,992 low molecular weight compounds comprising the NCI Diversity Set chemical library. A flow chart depicting the screening procedure is shown in Figure 3, and described in the Experimental Procedures. Following the initial automated screen, the images of the affected cells were inspected.
manually and a secondary screen was performed, in which hit compounds were tested at multiple concentrations, and directly compared to the well-established proteasome inhibitor MG132. This procedure resulted in the discovery of four compounds that induced nuclear translocation of PIR, indicating a hit rate of 0.2%. As summarized in Table 1, all four compounds detected in the primary screen were confirmed by manual inspection.

Biochemical Validation of the Inhibitory Effects of the Hit Compounds

One characteristic outcome of proteasome inhibition is the accumulation of ubiquitinated proteins in the treated cells. To monitor the levels of ubiquitinated proteins that accumulated upon incubation with the novel inhibitors detected in our screen, H1299-PIR cells were treated with each of the inhibitors for
A 6 hours, at doses comparable to those used in the screen. Following incubation, cell extracts were analyzed by Western blot, using anti-ubiquitin and anti-β-catenin antibodies. As shown in Fig. 4A&B, accumulation of endogenous polyubiquitinated proteins, as well as elevated levels of β-catenin (a known target of the proteasome), at varying degrees, were caused by all four inhibitors, confirming their inhibitory effect on proteasomal degradation. The hit compounds NSC321206 (at a concentration of 0.15 μM) and NSC310551 (0.3 μM) were the most effective, demonstrating inhibitory activity comparable to that of 5 μM MG132. NSC99671 and NSC3907 (50 μM and 20 μM, respectively) displayed less of an inhibitory effect. It is noteworthy that the same concentrations that induced nuclear transport in the PIR assay, also resulted in accumulation of polyubiquitinated proteins and stabilization of β-catenin. Moreover, the potency of proteasomal inhibition, judged by these criteria, coincides nicely with the magnitude of the nuclear fluorescence signal detected in the PIR cell-based assay, upon inhibition with the different hit compounds.

To directly test the capacity of the four compounds to inhibit activity in mammalian proteasomes, we performed an in vitro activity assay in which the hit compounds were tested for their effects on the degradation of the model fluorogenic tetrapeptide LLVY-AMC by purified rabbit 26S proteasomes. As seen in Fig. 4C, all four compounds inhibited proteasomal degradation to varying degrees. Both NSC310551 and NSC321206 showed levels of inhibition comparable to that of MG132, with NSC321206 being the most effective inhibitor. NSC99671 displayed a moderate inhibitory effect, and NSC3907 had only a minor effect. The low potency of NSC3907 in inhibiting the purified proteasome Inhibitors Screen

Figure 2. MDM2 promotes PIR nuclear translocation. (A) Overexpression of MDM2 results in the PIR nuclear localization without additional stimuli. PIR cells were transfected with wild-type MDM2, MDM2 mutant deficient on p53 binding (Δ 9-58), or MDM2 mutant with abolished E3 ligase site (Ser 440). Cells expressing both p53 and MDM2 were visualized by immunofluorescence staining with the anti-MDM2 monoclonal antibodies. PIR has a nuclear localization in the cells expressing wt MDM2 and MDM2 (Ser 440), and remains cytoplasmic in the cells transfected with MDM2 (Δ 9-58). (B) Mdm2 siRNA prevents bortezomide–induced translocation of PIR to the nucleus. PIR cells were transiently transfected with 200 pmol control-siRNA or Mdm2-siRNA. Forty-eight hours after transfection, bortezomide (0.1 μM) was added for an additional 6 h, and immunofluorescence staining for MDM2 was performed as described in Materials and Methods. doi:10.1371/journal.pone.0008503.g002
proteasome was consistent with previous findings [33,34], showing that this molecule (8-Hydroxyquinolinol salicylate) can specifically inhibit the chymotryptic activity of the proteasome only in complex with intracellular copper. The fact that this compound was still picked up by our screen reflects an advantage of this cell-based assay.

Effect of the Novel Proteasome Inhibitors on Cell Viability

Proteasome inhibitors are known to be particularly cytotoxic to malignant cells via multiple mechanisms [7,35]. To directly test the effects of the new proteasome inhibitors discovered in this study on cell viability, we treated PIR-expressing H1299 cells for 48 h with each of the four compounds, at a wide range of concentrations, ranging from 0.1 to 100 μM. The cells were then subjected to an Alamar Blue viability assay, which quantifies the number of metabolically active cells. As shown in Fig. 5, all four compounds affect cell viability, or inhibit the growth of PIR-H1299 cells (independent of the presence of PIR), at different concentrations. NSC3907 and NSC99671 exhibited a relatively weak growth inhibition effect, with GI\textsubscript{50} values of 47 μM and 96 μM, respectively, while NSC310551 and NSC321206 displayed a considerably stronger effect, with GI\textsubscript{50} values of 0.27 μM and 0.17 μM, respectively. For all proteasome inhibitors examined in this screen, there was a high correlation between proteasomal inhibitory activity and cell viability.

In view of previous reports, indicating that malignant cells are significantly more sensitive to proteasome inhibition than their normal counterparts [7,36], we compared the effect of the most effective inhibitory compound, NSC321206, toward normal breast epithelial cell line (MCF10A) and malignant breast carcinoma cells (MDM-MB-231) cell lines. As shown in Fig. S1, NSC321206 effectively eliminated all MDA-MB-231 cells at a concentration of 1 μM (GI\textsubscript{50} value of 0.4 μM), while the non-malignant breast epithelial cell line (MCF10A) were only partially affected, at a considerably higher concentration of this compound.

To gain insights into the effects of our hit compounds on a wide variety of cells, we explored the published information on the effects of these compounds on the NCI-60 panel of human tumor cell lines used in the NCI Developmental Therapeutics Program (DTP) (http://dtp.nci.nih.gov). As seen in Figure S2, the four hit compounds showed cytotoxic effects (log\textsubscript{10} GI\textsubscript{50} ≤−4.0) against a variety of cell lines, whereas NSC321206 and NSC310551 demonstrated high cytotoxicity in vitro against all tested human cancer cell lines in the panel, with average negative log\textsubscript{10} GI\textsubscript{50} values of 7.2 and 6.6, respectively. The activity of NSC3907 was much lower, with a mean overall − log\textsubscript{10} GI\textsubscript{50} value of 5.3. NSC99671 was non-toxic for most of the lines (overall − log\textsubscript{10} GI\textsubscript{50} of 4.1). The most sensitive cell lines for all hit compounds were the leukemia cells, with overall − log\textsubscript{10} GI\textsubscript{50} equaling 7.73 for NSC321206, 7.028 for NSC310551, 6.249 for NSC3907, and 4.473 for NSC99671. These initial findings corroborate our in vitro results, and directly demonstrate the use of our novel proteasomal inhibitors as potential therapeutic agents in cancer.

Discussion

Presently, few approaches for the high-throughput discovery of proteasome inhibitors exist [18,19,20], those that do, are mostly based on the use of biochemical techniques. Cell-based/image-based assays enables evaluation of potential proteasomal inhibitors that may not be detected using purified proteasomes and have several other advantages such as demonstrating that active compounds are cell-permeable and are sensitive to effects at multiple targets and nodes within a given pathway, as opposed to a strict cell-free assay that focuses on one particular target, such as degradation of a particular substrate by a purified proteasome. The main motivation directing the development of PIR was to establish a method enabling the assessment of
proteasomal inhibition in a cellular context, based on the unequivocal translocation of a fluorescent reporter protein from the cytoplasm to the nucleus upon proteasomal inhibition, without grossly affecting its overall levels. We found this approach to be highly specific, with essentially no false positives, in contrast to existing cell-based screens for proteasomal inhibitors that monitor the accumulation of fluorescent signals from direct proteasomal substrates [21,22,23], that appear to be sensitive to autofluorescence and to the fluorescence-quenching effects of the screening molecules, as well as to variations in cell geometry, some of which may be induced, directly or indirectly, by proteasomal inhibition.

The design of the PIR reporter protein is based on a p53 R175H mutant which, in contrast to the short-lived, WT p53, has a significantly longer half-life (several hours), presumably due to its reduced susceptibility to proteasomal degradation [37]. As a result, the overall concentration of PIR in cells is only marginally affected by treatment with proteasomal inhibitors such as MG132 (Fig. 1C). In the PIR assay, monitoring proteasomal inhibition is based on intracellular translocation of the reporter protein from the cytoplasm to the nucleus, in response to proteasomal inhibition. It is noteworthy that PIR was found to be particularly suitable for high throughput screening for proteasomal inhibitors, due to the unambiguous quantification of nuclear vs. cytoplasmic fluorescence.

Several proteins such as p53, MDM2 and β-catenin were previously reported to accumulate in the nucleus following treatment with proteasome inhibitors [32,38,39,40,41,42]. Beyond the fact that these are all target substrates of the ubiquitin-proteasome pathway, their translocation to the nucleus is mediated via recognition of their NLS by cytosolic nuclear transport receptors [apart from β-catenin, which is imported into the nucleus by direct binding to the nuclear pore machinery [43]]. Typically, deletion or mutation of the NLS disrupts their nuclear import. Under normal cell culture conditions, PIR, which is based on R175H p53 with a mutated bipartite NLS [29], loses its ability to translocate to the nucleus and, therefore, accumulates in the cytoplasm. Even treatment with etoposide, which is a strong inducer of p53 cytoplasm-to-nucleus transport, fails to promote this translocation. Our studies provide some clues as to the mechanism underlying PIR translocation.

**Figure 4. Positive hit compounds inhibit 26S proteasome.** (A) PIR cells were treated with hit compounds and MG132 for 6 hr at the following concentrations: NSC3907 – 20 μM; NSC99671 – 50 μM; NSC310551 – 0.3 μM; NSC321206 – 0.15 μM; and MG132 - 5 μM. Whole cell lysates were immunoblotted for ubiquitin (upper panel) and β-catenin (middle panel) and β-tubulin (lower panel) was used as an internal loading control. (B) Quantitation of the amounts of ubiquitinated proteins (blue) and β-catenin (red) in the absence of and upon treatment with the different inhibitors. (C) Positive hit compounds inhibit purified proteasome in vitro. Purified 26S proteasomes from rabbit muscle were incubated for the indicated times in the presence of 30 μM of our positive hits (100 μM for NSC3907). MG-132 at a 5 μM concentration served as a positive control. NSC3907 (blue), NSC99671 (green), NSC310551 (magenta), NSC321206 (orange), without treatment (red) and MG-132 (black).

doi:10.1371/journal.pone.0008503.g004

**Figure 5. Effect of the hit compounds on the viability of PIR cells.** PIR cells were treated with the active compounds for 48 hr at 11 concentrations ranging from 0.1 to 100 μM and the cells’ viability was assessed by AlamarBlue assay. Results are expressed as the viability ratio of treated to untreated cells and represent the mean ± SD of 6 repeats.

doi:10.1371/journal.pone.0008503.g005
translocation to the nucleus upon proteasomal inhibition. Specifically, we propose a model suggesting that nuclear entry of this molecule is driven by yet another protein, which is highly sensitive to proteasomal degradation, contains a nuclear localization domain, and is capable of piggy-backing PIR into the nucleus. Furthermore, we provide evidence suggesting that this nuclear translocator of PIR is, in fact, the p53 E3 ubiquitin ligase MDM2, which was shown to translocate into the nucleus upon proteasome inhibition (Xirodimas et al 2001). MDM2 promotes PIR nuclear import in transiently transfected cells over-expressing wild type MDM2, in the absence of additional stimuli (Fig. 2). Upon proteasome inhibition, the levels of MDM2 dramatically increase and, if it enters, drive PIR into the nucleus. We also demonstrated that the ability of MDM2 to bind p53 is critical for such translocation, unlike its E3 ubiquitin ligase function. Further compelling support for our model comes from the fact that the translocation of the PIR protein to the nucleus, induced by proteasome inhibition, is abolished by MDM2 knockdown, confirming that the interaction between the two proteins results in colocalization in the nucleus. This is consistent with previous reports showing that wild type p53 (as well as its homologue p73) and MDM2 may facilitate the shuttling of each other from the cytoplasm into the nucleus [31,44] and vice versa.

In conclusion, the novel cell-based screen described here appears to be a robust and highly sensitive tool for the identification of new proteasome inhibitors. It is based on the stabilized MDM2-dependent accumulation of the PIR molecule in the nucleus, and is compatible with microscopy-based high throughput screening technology. Further characterization of the new inhibitors discovered using this approach, as well as the development of a combined ultra high resolution / high content screen, based on the PIR cells, are currently underway.

References

1. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67: 403–479.
2. Hochstrasser M (1996) Protein degradation or regulation: Ub the judge. Cell 84: 813–815.
3. Groll M, Ditzel I, Lowe J, Stock D, Bocheier M, et al. (1997) Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386: 463–471.
4. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, et al. (1993) Crystal structure of the 20S proteasome from the archaean T. acidophilum at 3.4 Å resolution. Science 268: 533–539.
5. Orlofski M, Cardozo C, Michaud C (1993) Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteasome complex. Properties of two components cleaving bonds on the carbonyl side of branched chain and small neutral amino acids. Biochemistry 32: 1563–1572.
6. Imajoh-Ohmi S, Kawauchi T, Sugiyama S, Tanaka K, Oamura S, et al. (1995) Lactacytin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217: 1067–1070.
7. Orlofski RZ, Esware JR, Laband-Walker A, Grever MR, Orlofski M, et al. (1996) Tumor growth inhibition induced in a marine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 56: 4342–4348.
8. Adams J, Kauflin M (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 22: 304–311.
9. Cavas M (2006) Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 20: 1341–1352.
10. Ocino EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF (2008) New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 9: 1175–1186.
11. Richardson PG, Anderson KC (2001) Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 1: 596–600.
12. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739–758.
13. Tsukamoto S, Yokosawa H (2006) Targeting the proteasome pathway. Expert Opin Ther Targets 13: 605–621.
14. Corey EJ, Li WD (1999) Total synthesis and biological activity of lactacystin, omuralide and analogs. Chem Pharm Bull (Tokyo) 47: 1–10.
15. Chauhan D, Catley L, Li G, Podor K, Hileshtima T, et al. (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell II: 407–419.
16. Dento SD, Kij JM, Aujay MA, Buchholz TJ, Dajeec M, et al. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67: 6383–6391.
17. Miller CP, Ban K, Dujka MB, McConkey DJ, Munsell M, et al. (2007) NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110: 267–277.
18. Barks BJ, Harris JL, Leonetti F, Craik CS, Ellman JA (2006) Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin. Nat Biotechnol 13: 187–193.
19. Harris JL, Barks BJ, Leonetti F, Mahrus S, Ellman JA, et al. (2000) Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci U S A 97: 7754–7759.
20. Moravec RA, O’Brien MA, Daily WJ, Scuoria MA, Bernad L, et al. (2009) Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format. Anal Biochem 387: 294–302.
21. Dantuma NP, Lindsten K, Glas R, Jelline M, Maucci MG (2000) Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent protein turnover in living cells. Nat Biotechnol 18: 538–543.
22. Bence NF, Sampart RM, Kopeko RR (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552–1555.
23. Andreotta C, Nahreini P, Howland AR, Kumar B, Edwards-Prasad J, et al. (2001) Use of short-lived green fluorescent protein for the detection of proteasome inhibition. Biotechniques 39: 656–660.
24. Nicolini I, Zender S, Sause F, Geffers R, Brandes G, et al. (2008) Argynin reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 14: 23–35.
25. Hijri RC, Krummel B, Saiki RK (1988) A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res 16: 7351–7367.

Supporting Information

Figure S1 Differential effect of NSC321206 on human malignant breast cells (MDM-MB-231) and human non-malignant breast epithelial cells (MCF10A). The two cell lines were treated with NSC321206 for 48 hr at 6 concentrations ranging from 0.025 to 2.5 µM and the viability was assessed using the AlamarBlue assay. Results are expressed as the viability ratio of treated to untreated cells and represent the mean ± SD values of 6 repeats. Found at: doi:10.1371/journal.pone.0008503.s001 (2.12 MB TIF)

Figure S2 In vitro cytotoxicity of the hit compounds on an NCI-60 panel of human tumor cell lines. Results are based on data from anti-cancer drug screening against the full panel of 60 human cancer cell lines, conducted as part of the Developmental Therapeutics Program at the National Cancer Institute (http://dtp.nci.nih.gov). The panel is divided into nine sub-panels representing diverse cancer cell types, including leukemia, melanoma, and cancers of the lung, colon, kidney, ovary, breast, prostate, and central nervous system. Results obtained with this test are expressed as the -log of the molar concentration that inhibited cell growth by 50% (-log GI50 >4.00 for active compounds). Found at: doi:10.1371/journal.pone.0008503.s002 (4.24 MB TIF)

Acknowledgments

We would like to thank Barbara Morgenstern for editorial assistance.

Author Contributions

Conceived and designed the experiments: IL VR MO AN BG. Performed the experiments: IL AB AN. Analyzed the data: IL VR MO AN BG. Performed the proteasome inhibitors screen: AN BG. Contributed reagents/materials/analysis tools: IL. ZK VR MO BG. Wrote the paper: IL AN BG.
26. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51–59.

27. Paran Y, Lavelin I, Naffar-Abu-Amara S, Winograd-Katz S, Liron Y, et al. (2006) Development and application of automatic high-resolution light microscopy for cell-based screens. Methods Enzymol 414: 228–247.

28. Liron Y, Paran Y, Zatorsky NG, Geiger B, Kam Z (2006) Laser autofocus system for high-resolution cell biological imaging. J Microsc 221: 145–151.

29. O’Keefe K, Li H, Zhang Y (2003) Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol 23: 6396–6405.

30. Liang SH, Clarke MF (1999) A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain. J Biol Chem 274: 32699–32703.

31. Yu ZK, Geyer RK, Maki CG (2000) MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene 19: 5892–5897.

32. Salomon D, Sacco PA, Roy SG, Simcha I, Johnson KR, et al. (1997) Regulation of beta-catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system. J Cell Biol 139: 1325–1335.

33. Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, et al. (2007) Clioquinol, a therapeutic agent for Alzheimer’s disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res 67: 1636–1644.

34. Daniel KG, Gupta P, Harbach RH, Guirda WC, Dow QP (2004) Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 67: 1139–1151.

35. Voorbees PM, Orlowski RZ (2006) The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46: 189–213.

36. Almond JB, Cohen GM (2002) The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433–443.

37. Zambrini GP, Levine AJ (1993) A comparison of the biological activities of wild-type and mutant p53. Faec. J 7: 855–865.

38. Bonvini P, Hwang SG, El-Gamil M, Robbins P, Kim JS, et al. (2000) Nuclear beta-catenin displays GSK-3beta- and APC-independent proteasome sensitivity in melanoma cells. Biochim Biophys Acta 1495: 308–318.

39. Kilhanov SA, O’Hagan HM, Ljungman M (2001) Accumulation of soluble and nucleolar-associated p53 proteins following cellular stress. J Cell Sci 114: 1867–1873.

40. Latorre L, Kiuriki S, Pitkanen K, Laiho M (2003) p53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction. Cell Signal 15: 95–102.

41. Stommel JM, Wahl GM (2004) Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. Embo J 23: 1547–1556.

42. Xirodimas D, Saville MK, Edling C, Lane DP, Lain S (2001) Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 20: 4972–4983.

43. Fagotto F, Gluck U, Gumbiner BM (1998) Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 8: 181–190.

44. Dobbelstein M, Wierzuw S, Konig G, Roth J (1999) Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18: 2101–2106.